English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduIn mourning of the death of Alex Trebek,Timothy Donahue, MD, chief of surgical oncology at UCLA’s Jonsson Comprehensive Cancer Center is available to discuss complications from metastatic cancer of the pancreas and the advances in treatment for pancreatic cancer.
More from Dr. Donahue:
No screening test exists for pancreatic cancer. And while some patients may experience “painless jaundice” as a warning sign, many other symptoms of the disease — back pain, abdominal pain, decreased energy, weight loss — are so general that diagnoses often come at later stages, says Dr. Donahue.
Pancreatic cancer is also particularly aggressive and resistant to most treatments, including conventional chemotherapies, targeted therapies and immunotherapies.
Risk factors including smoking and drinking alcohol, “but they’re not really strong risk factors,” says Dr. Donahue.
“Most people are innocent victims of their disease and live healthy, upstanding lives,” he says.
One of the most effective preventive measures, particularly for those with a family history of cancer, is germline sequencing, which can detect gene mutations known to increase disease risk. This kind of DNA mapping has created more potential treatment options in recent years, Dr. Donahue says.
Emerging research centers on a specific oncogene, or cancer-causing genetic mutation, known as KRAS, which drives tumor growth in the pancreas. Much like mutations of the BRCA gene increase risk of breast cancer, KRAS mutations are implicated in nearly all pancreatic cancer cases.
“There have been recent breakthroughs of drugs that target some of the variants of the KRAS oncogene,” Dr. Donahue says. “And there is hope that this might be the start to really cracking the nut, so to speak, of pancreatic cancer and a potential so-called magic bullet against the tumor.”
About 8 percent of late-stage pancreatic cancer patients also exhibit mutations of the BRCA gene.
“Now that we know this information, we’re able to screen patients who have BRCA mutations better, like with frequent MRI exams or even endoscopies of the pancreas,” Dr. Donahue says. “So if they were to develop a pancreatic cancer, the hope and the goal is to diagnose it earlier so these patients would be eligible for surgery with curative intent.”
Other recent treatment advances include the development of robotic-assisted surgery, which is as effective as open surgery but with quicker recovery times.
“I am optimistic that both medical and surgical therapies for this disease are going to continue to improve,” Dr. Donahue says, “and hopefully continue to improve the prognosis of patients with this disease.”
